Full-Time
Leveraged Finance
Vice President
Jefferies
5,001-10,000 employees
Global investment banking and capital markets
No salary listed
London, UK
In Person
 Finance & Banking (1) |
|---|
- 6–8+ years of relevant experience in leveraged finance, debt capital markets, or related investment banking roles
- Proven track record executing leveraged loan and/or high‑yield transactions in EMEA
- Advanced financial modelling and analytical capabilities with strong attention to detail
- Strong understanding of leveraged credit markets, documentation, investor dynamics, and rating processes
- Excellent written and verbal communication skills; confident presenting to internal and external stakeholders
- Demonstrated ability to lead deal teams and manage multiple workstreams under tight timelines
- Collaborative mindset with the ability to work effectively across functions and geographies
- Lead day‑to‑day execution of leveraged finance transactions, including LBO financing, acquisition financing, and refinancings
- Oversee preparation and review of financing materials, including lender presentations, rating agency materials, offering memoranda, and internal approval documents
- Manage financial modelling and capital structure analysis; ensure quality and accuracy across all materials
- Coordinate due diligence processes, including Q&A with clients, advisors, and internal teams
- Drive engagement with loan and bond investors, ratings agencies, legal counsel, and internal stakeholders
- Support senior bankers in the origination of new leveraged finance mandates across sponsor and corporate clients
- Develop tailored financing ideas, capital structure solutions, and market updates for clients
- Participate in client meetings and contribute meaningfully to discussion and presentation delivery
- Build strong internal relationships across M&A, Sector Coverage, ECM, and Sales & Trading teams to drive integrated client coverage
- Maintain deep understanding of leveraged loan and high‑yield bond markets, investor sentiment, pricing trends, and structuring considerations
- Track relevant macroeconomic developments affecting financing markets
- Provide insight and guidance on optimal execution strategies for borrowers
- Manage, mentor, and develop Associates and Analysts; provide feedback, training, and oversight on deliverables
- Ensure efficient workflow across deal teams; set expectations and drive strong performance culture
- Uphold Jefferies’ standards for quality, integrity, and client service
- 6–8+ years of relevant experience in leveraged finance, debt capital markets, or related investment banking roles
- Proven track record executing leveraged loan and/or high‑yield transactions in EMEA
- Advanced financial modelling and analytical capabilities with strong attention to detail
- Strong understanding of leveraged credit markets, documentation, investor dynamics, and rating processes
- Excellent written and verbal communication skills; confident presenting to internal and external stakeholders
- Demonstrated ability to lead deal teams and manage multiple workstreams under tight timelines
- Collaborative mindset with the ability to work effectively across functions and geographies
- None
Jefferies is a global, full‑service investment banking and capital markets firm that helps investors, companies, and governments with advisory services, sales and trading, research, and wealth and asset management. It uses a worldwide network of more than 40 offices to deliver market insights and financial solutions to clients. Its products include advisory services for mergers and restructurings, capital markets execution, securities research, and portfolio management for individuals and institutions. The goal is to guide clients through financial markets, raise capital, and grow wealth across geographies and asset classes.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
New York City, New York
Founded
1854
Simplify's Take
What believers are saying
- SMFG's 20% stake and Hyakutome board nomination strengthen Jefferies' global alliances.
- India's 2024 IPO boom with $21B raised expands Jefferies' equity underwriting opportunities.
- $162B global secondary trading volume in 2024 boosts Jefferies' capital markets revenue.
What critics are saying
- SMFG's 20% stake triggers hostile takeover, diluting Jefferies shareholders in 12-24 months.
- Biotech offerings like Intellia $150M fail amid trial setbacks, slashing underwriting fees.
- Parfums de Marly €2B sale collapses post-Sprecher exit, damaging Jefferies advisory reputation.
What makes Jefferies unique
- Jefferies leads high-profile mandates like Parfums de Marly €2B sale with Goldman Sachs.
- Jefferies underwrites major biotech offerings including Intellia $180M and Kailera $625M IPOs.
- Jefferies upgrades retail stocks like Boot Barn to Buy, driving 16% sales growth analysis.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Jefferies who can refer or advise you
Benefits
Health Insurance
Life Insurance
Wellness Program
Company News
FTI Consulting appoints Mike Davies to Capital Markets practice. London, 27 April 2026 - FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Mike Davies as a Senior Managing Director within the firm's Strategic Communications segment. Mr. Davies, who is based in London, brings more than 25 years of investment banking experience, with deep expertise across capital markets in the Europe, Middle East and Africa ("EMEA") region. Throughout his career, he has advised boards and C-suite leaders on high-profile transactions, IPOs and investor engagement strategies, building strong relationships with senior portfolio managers across the investment community. In his role at FTI Consulting, Mr. Davies will join the Capital Markets practice within the Strategic Communications segment, where he will help clients navigate complex market situations, with a focus on equity story development, investor engagement and transaction communications. "Mike brings exceptional experience from the heart of the EMEA capital markets ecosystem, with a track record of advising senior leaders through high-stakes transactions and market-facing situations," said Charles Armitstead, UK Head of the Strategic Communications segment at FTI Consulting. "As market conditions become increasingly complex and investor scrutiny intensifies, his expertise further enhances our ability to support clients across the full capital markets lifecycle. Mike's appointment reflects our continued investment in senior talent as we build on FTI Consulting's long-standing leadership in this space." Prior to joining FTI Consulting, Mr. Davies spent more than a decade at Jefferies, most recently serving as Head of Sales, EMEA Equities. As a senior leader within the firm's European equities and investment banking franchise, he helped drive the growth of its equity capital markets and institutional client business across the region. Earlier in his career, he held senior positions at J.P. Morgan Cazenove and UBS. Commenting on his appointment, Mr. Davies said, "I'm delighted to be joining FTI Consulting and begin this exciting new chapter in my professional career with such talented colleagues. I'm greatly looking forward to helping grow and expand the Capital Markets practice, develop new client relationships and enhance the firm's competitive position." Mr. Davies' appointment follows a series of recent senior hires in FTI Consulting's Strategic Communications segment in the UK, including Senior Managing Director Benedict Brogan and Managing Director Duncan Mavin, as the firm continues to invest in its capabilities to meet growing client demand. About FTI Consulting FTI Consulting, Inc. is a leading global expert firm for organisations facing crisis and transformation, with more than 8,100 employees located in 32 countries and territories as of December 31, 2025. In certain jurisdictions, FTI Consulting's services are provided through distinct legal entities that are separately capitalised and independently managed. The Company generated $3.80 billion in revenues during fiscal year 2025. More information can be found at www.fticonsulting.com. FTI Consulting, Inc. 200 Aldersgate Aldersgate Street London, EC1A 4HD Media contacts. * Corporate Communications Matthew Bashalany +1 617 897 1545 * Americas - U.S. (East Coast, Midwest) Sam Ford +1 617 480 7402 * Americas - U.S. (West Coast), Latin America Nick Emmons +1 617 747 1708 * Europe, Middle East, Africa Helen Obi +44 79 7759 1658 * Asia Yammie Ng +852 3768 4560 * Australia Rebecca Hine +61 7 3225 4972
ARRAY Technologies, a global provider of solar tracking technology, has increased its revolving credit facility from $166 million to $370 million and extended the maturity date from October 2028 to February 2031. The amended facility includes up to $250 million available for letters of credit. Goldman Sachs Bank USA served as lead arranger and administrative agent, with participation from JP Morgan, Wells Fargo Securities, PNC Capital Markets and HSBC Bank USA. The company welcomed three new lenders to its syndicate. The enhanced facility will support operational execution, working capital needs and global growth initiatives. Chief financial officer Keith Jennings said the expansion demonstrates lender confidence in the company's strategy and position as a global leader in utility-scale solar.
Xponential Fitness exploring sale after investor pressure mounts. April 7, 2026 1/3 free articles used this month. The board of the Club Pilates and Pure Barre parent has hired Jefferies to evaluate strategic alternatives, including a potential sale or merger. Xponential Fitness' board says it's exploring a sale, an announcement that follows weeks of shareholder pressure. In March, Houston-based Voss Capital - the company's biggest shareholder, controlling 19.3% of outstanding shares - issued an open letter urging the board to hire independent financial advisors and explore a full sale. Kanen Wealth Management, which owns roughly 4% of Xponential's shares, followed with its own public demand on April 1. The boutique fitness franchisor operates five brands within its portfolio, Club Pilates, Pure Barre, YogaSix, BFT and StretchLab, down from 11 brands around two years ago. Xponential has tapped Jefferies LLC as its financial advisor for the review, during which the board's independent directors will evaluate a range of potential alternatives, including a sale, merger or other strategic or financial transaction, the company said. The board has also appointed Nicole Parent Haughey, a former Fortune 50 executive and founder of Halsey Loganberry Growth Advisors, as an independent director. Jair Clarke, Chelsea A. Grayson and Bruce Haase have stepped down from the board. CEO Mike Nuzzo, who took the helm last August, succeeding Mark King, said the company would continue executing its strategy while the review proceeds.
Jefferies has analysed potential 100% tariffs on certain pharmaceutical imports following reports that the Trump administration is preparing new levies under a Section 232 investigation. The tariffs would apply to companies without White House deals, whilst imports from countries with trade agreements would be capped at negotiated terms. The investment bank believes generic drugs will likely remain exempt, as tariffs on generics could trigger drug shortages due to thin margins and supply chain disruptions. Among Indian pharmaceutical companies, Sun Pharma faces the highest exposure, with innovative medicines comprising roughly 20% of its revenue. However, Jefferies expects tariffs on Sun Pharma's innovative products to be capped at 15%, as key manufacturing locations South Korea and the EU have negotiated that rate.
Lexicon Pharmaceuticals has closed a $32 million public offering, selling 32 million shares at $1.30 each, alongside a private placement including preferred stock. The Nasdaq-traded biotech aims to fund late-stage programmes for neuropathic pain and cardiometabolic diseases as cash reserves fell to $125.2 million by end-2025. The company's pilavapadin candidate for neuropathic pain is licensed to Novo Nordisk under a deal worth up to $1 billion in milestones plus royalties. A recent trial initiation triggered a $10 million payment. Lexicon also plans to file an NDA in 2026 for sotagliflozin in hypertrophic cardiomyopathy. The stock dipped approximately 2% post-announcement due to dilution concerns. Fourth-quarter 2025 revenues are projected at $3.14 million, down 88% year-over-year.